This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greatbatch, Inc. Reports 2011 Fourth Quarter And Full Year Results

Selling, general and administrative (“SG&A”) expenses increased to $18.6 million, or 13.1% of sales, for the fourth quarter of 2011 compared to $15.3 million, or 11.5% of sales, for the same period of 2010. For the year, SG&A costs were $72.5 million, or 12.8% of sales, versus $64.5 million, or 12.1% of sales for 2010. The change in SG&A expenses for the quarter and full year included the impact of higher legal and regulatory consulting costs incurred in connection with our medical device initiatives ($1.6 million quarter, $4.0 million full year), higher performance based compensation ($0.8 million quarter, $3.9 million full year), and the negative impact of strengthening foreign currencies on the cost of our international operations ($0.09 million quarter, $1.1 million full year) in comparison to the prior year. Additionally, SG&A for the fourth quarter of 2011 included approximately $0.4 million of costs related to the operations of Micro Power.

Net research, development and engineering costs (“RD&E”) for the 2011 fourth quarter were $12.8 million, or 9.0% of sales, compared to $11.4 million, or 8.6% of sales, for the corresponding 2010 period. For 2011, net RD&E costs totaled $45.5 million, or 8.0% of sales, versus $45.0 million, or 8.4% of sales for 2010. During the fourth quarter of 2011, the Company incurred $6.7 million ($23.3 million full year) of RD&E expenses related to the development of complete medical devices, compared to $3.7 million ($20.3 million full year) for the corresponding 2010 periods, respectively. More specifically, included in fourth quarter 2011 amounts are $2.3 million ($5.1 million full year) of design verification testing (“DVT”) costs related to the QiG Group’s development of a neuromodulation platform. Partially offsetting these increases was a higher level ($0.7 million quarter, $2.4 million full year) of customer cost reimbursements in comparison to the 2010 period. These cost reimbursements can vary significantly due to the timing of the achievement of milestones on development projects.

3 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,077.62 -450.41 -2.73%
S&P 500 1,922.45 -49.73 -2.52%
NASDAQ 4,662.0120 -114.4960 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs